Veromaa was President and CEO of Biotie Therapies Corporation for over 11 years until its acquisition by Acorda Therapeutics in 2016.  During this period, he achieved significant growth in the company, including the launch of the opioid antagonist Selincro, and a listing on the US Nasdaq stock exchange. During his earlier career, Veromaa was a Medical Director of Schering Ltd. in Finland, Senior Scientist and Project Director at Collagen Corporation and a Postdoctoral Fellow at Stanford University in California. He is a medical doctor with a PhD in immunology from the University of Turku, Finland.